Minerva Neurosciences (NASDAQ:NERV) Coverage Initiated by Analysts at StockNews.com

StockNews.com started coverage on shares of Minerva Neurosciences (NASDAQ:NERV) in a report published on Wednesday morning. The brokerage issued a sell rating on the biopharmaceutical company’s stock.

Separately, HC Wainwright lowered their price target on Minerva Neurosciences from $7.00 to $5.00 and set a neutral rating for the company in a report on Wednesday, August 7th.

Minerva Neurosciences Trading Up 0.7 %

Minerva Neurosciences stock traded up $0.02 during midday trading on Wednesday, reaching $2.85. 11,051 shares of the stock traded hands, compared to its average volume of 67,318. The firm has a market cap of $19.93 million, a PE ratio of -0.63 and a beta of 0.15. Minerva Neurosciences has a 12-month low of $2.26 and a 12-month high of $13.49. The company has a 50-day simple moving average of $3.17 and a two-hundred day simple moving average of $3.74.

Minerva Neurosciences (NASDAQ:NERV) last announced its quarterly earnings data on Tuesday, August 6th. The biopharmaceutical company reported ($1.09) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.97) by ($0.12). Equities research analysts anticipate that Minerva Neurosciences will post -1.89 earnings per share for the current year.

About Minerva Neurosciences

Minerva Neurosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone (MIN-101) for the treatment of negative symptoms in patients with schizophrenia, currently submitted an New Drug Application (NDA); and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders.